MX2007012702A - Uso de anticuerpos cd25 en inmunoterapia. - Google Patents

Uso de anticuerpos cd25 en inmunoterapia.

Info

Publication number
MX2007012702A
MX2007012702A MX2007012702A MX2007012702A MX2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A MX 2007012702 A MX2007012702 A MX 2007012702A
Authority
MX
Mexico
Prior art keywords
immunotherapy
antibodies
administering
patient
treatment
Prior art date
Application number
MX2007012702A
Other languages
English (en)
Inventor
Andreas Katopodis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2007012702A publication Critical patent/MX2007012702A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un metodo para el tratamiento de enfermedad proliferativa o enfermedad infecciosa, que comprende administrar al paciente una cantidad efectiva de una molecula de union de CD25.
MX2007012702A 2005-04-15 2006-04-13 Uso de anticuerpos cd25 en inmunoterapia. MX2007012702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0507696.3A GB0507696D0 (en) 2005-04-15 2005-04-15 Organic compounds
PCT/EP2006/003444 WO2006108670A2 (en) 2005-04-15 2006-04-13 Use of cd25 antibodies in immunotherapy

Publications (1)

Publication Number Publication Date
MX2007012702A true MX2007012702A (es) 2008-01-14

Family

ID=34630783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012702A MX2007012702A (es) 2005-04-15 2006-04-13 Uso de anticuerpos cd25 en inmunoterapia.

Country Status (12)

Country Link
US (1) US20080171017A1 (es)
EP (1) EP1874349A2 (es)
JP (1) JP2008535883A (es)
KR (1) KR20070120146A (es)
CN (1) CN101160137A (es)
AU (1) AU2006233718A1 (es)
BR (1) BRPI0610635A2 (es)
CA (1) CA2600709A1 (es)
GB (1) GB0507696D0 (es)
MX (1) MX2007012702A (es)
RU (1) RU2007141994A (es)
WO (1) WO2006108670A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
CN103374074A (zh) * 2012-04-28 2013-10-30 中国科学院上海生命科学研究院 一种抗cd25单链抗体
CA2918325C (en) * 2013-07-18 2018-06-26 Toyama Chemical Co., Ltd. Benzopyran derivatives useful as inhibitors of macrophage migrration inhibitory factor
WO2017011592A1 (en) 2015-07-13 2017-01-19 Modular Genetics, Inc. Generation of acyl alcohols
RU2759970C2 (ru) * 2016-04-07 2021-11-19 Кансер Ресёрч Текнолоджи Лимитед БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN108084263B (zh) * 2016-12-16 2021-07-13 苏州旭光科星抗体生物科技有限公司 一种抗人cd25嵌合单克隆抗体及其制备方法和应用
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
SG11202008733YA (en) 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4151655A1 (en) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
WO2023196566A1 (en) * 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
TW202509067A (zh) * 2023-04-11 2025-03-01 大陸商蘇州創勝醫藥集團有限公司 抗ｃｄ２５抗體及其用途
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
CN1296386C (zh) * 2001-04-06 2007-01-24 布里斯托尔大学 Cd25结合分子在类固醇耐受型患者中的用途
BRPI0316282B8 (pt) * 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão

Also Published As

Publication number Publication date
BRPI0610635A2 (pt) 2010-07-13
GB0507696D0 (en) 2005-05-25
EP1874349A2 (en) 2008-01-09
CN101160137A (zh) 2008-04-09
AU2006233718A1 (en) 2006-10-19
KR20070120146A (ko) 2007-12-21
CA2600709A1 (en) 2006-10-19
RU2007141994A (ru) 2009-05-20
US20080171017A1 (en) 2008-07-17
WO2006108670A3 (en) 2006-12-28
JP2008535883A (ja) 2008-09-04
WO2006108670A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
MX2007012702A (es) Uso de anticuerpos cd25 en inmunoterapia.
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008085562A3 (en) Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TW200738270A (en) Method of treating depression using a TNFα antibody
WO2009010877A3 (en) Conjugate purification
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
IL190183A0 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MX2010006395A (es) Formulacion de anticuerpos.
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
WO2010066803A3 (en) Human antibodies against human tissue factor
EA200801930A1 (ru) Биспецифическая молекула, связывающая tlr9 и cd32 и содержащая t-клеточный эпитоп, для лечения аллергий
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MY147217A (en) Antibody molecules having specificity for human il-06
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
MY151051A (en) Vaccination against dengue virus infection
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200727791A (en) Materials and methods for improving livestock productivity
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
SI2380584T1 (sl) Imunostimulatorni postopek
MX2009004866A (es) Vacuna para enfermedad de lyme canina.
WO2010054377A3 (en) Fully human antibodies against n-cadherin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal